Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

“Prostate cancer feeds on testosterone,” explains ... ADT includes medications that affect the production of LHRH: LHRH agonists and LHRH antagonists. 2. LHRH agonists and LHRH antagonists ...

A total of 542 patients had received prior HT, predominantly LHRH agonists (53.7 %); of these, 455 had received prior LHRH analogue therapy (LHRH agonists or GnRH antagonists). Baseline PSA (media ...

With parenteral delivery, this risk seems to be equivalent to that associated with orchiectomy, LHRH agonists ... supported by the National Cancer Research Network Prostate Cancer UK studies ...

An Ancillary Study of the STAMPEDE Docetaxel Trials Ruth Langley presented results from a phase 3 trial comparing transdermal estradiol to LHRH agonists for androgen suppression in M0 prostate cancer.

DelveInsight’s, “Metastatic Prostate Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies and 85+ pipeline drugs in metastatic prostate cancer pipeline landscape. It ...

79 patients with prostate cancer all received androgen receptor pathway inhibitor drugs. In addition, they were randomly assigned to receive either LHRH drugs or a transdermal patch containing ...

Alarming Rise in Rates of Advanced Prostate Cancer in California Feb. 3, 2025 — The incidence of advanced prostate cancer in California rose markedly in the decade since doctors stopped ...

When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the ...

Prostate cancer has become England's most common cancer as more men are getting checked. Prostate Cancer UK analysis shows diagnoses of the disease overtook breast cancer in 2022 and 2023.

Although carbon ion radiation led to a decline in urinary function among patients with prostate cancer, function returned to normal after three months. Among those with intermediate-risk prostate ...